Objective:

To compare the efficacy and safety of high-dose etoposide combined with PEG-rhG-CSF versus high-dose etoposide combined with rhG-CSF specifically for hematopoietic stem cell mobilization in patients with lymphoma and multiple myeloma.

Key Findings:

• Mobilization success exceeded 90% in both groups, with statistical significance noted.
• The PEG-rhG-CSF group achieved a significantly higher total CD34+ cell yield (p-value).
• The PEG-rhG-CSF group had a greater proportion of optimal mobilizers and a higher first-day collection success rate (p-value).
• Fewer apheresis sessions and shorter mobilization duration were observed in the PEG-rhG-CSF group (p-value).
• The incidence of febrile infection was significantly lower with PEG-rhG-CSF (p-value).

Interpretation:

High-dose VP-16 combined with PEG-rhG-CSF demonstrated superior efficacy, safety, and procedural efficiency compared to high-dose VP-16 plus rhG-CSF.

Limitations:

• Retrospective study design may introduce bias, potentially affecting the reliability of the results.
• Limited sample size of 71 patients may restrict the generalizability of the findings.

Conclusion:

The findings suggest that high-dose VP-16 combined with PEG-rhG-CSF may be a preferable alternative for hematopoietic stem cell mobilization in patients with multiple myeloma or lymphoma, with implications for improving patient outcomes.